



PRESS RELEASE

Professor Marc Feldmann Joins Trillium Therapeutics' Scientific Advisory Board

Toronto, Canada – June 8, 2004 - Trillium Therapeutics Inc. (TTI) today announced that Dr. Marc Feldmann, a Professor at Imperial College London and Head of the Kennedy Institute of Rheumatology Division, has agreed to join the company's Scientific Advisory Board (SAB). Dr. Feldmann is welcomed to the board by fellow members Drs. Mohamed Sayegh, Vijay Kuchroo, Brian Barber and Gary Levy.

"Marc Feldmann is a pioneer in cytokine research and his work in the TNF field is benefiting an ever increasing number of patients with autoimmune disorders", commented Dr. Niclas Stiernholm, TTI's Chief Executive Officer. "His experience and knowledge will provide us with an invaluable resource as we advance both our CD200 development candidate and our new cytokine antagonist program towards the clinic."

Dr. Marc Feldmann, Head of Kennedy Institute of Rheumatology Division at the Imperial College London, is a leader in the field of TNF research and his work has paved the way for today's blockbuster TNF-blocking drugs, which are now used in a variety of autoimmune disorders. He has authored over 600 scientific articles, has written and edited several books and serves on the editorial boards of a variety of scientific journals. Dr. Feldmann is the recipient of many awards, including the 2000 Crafoord Prize of the Royal Swedish Academy and 2003 Albert Lasker Clinical Research Award. He is an inventor on numerous patents and is the founder of the 2001 start-up company, Synovis.

Trillium Therapeutics Inc. is a privately held Research and Development company that specializes in the development of innovative therapies that restore balance to the immune system in conditions associated with aberrant and harmful immune responses. These include autoimmune and inflammatory disorders, graft rejection, cancer and viral hepatitis. The Company identifies therapeutic candidates with promising preclinical profiles and advances these into clinical testing, with the primary objective of demonstrating safety and efficacy in humans. TTI

currently has three development programs, one based on the CD200 immunoregulatory protein and its receptor, a second targeting the novel pro-thrombinase Fgl2, and a third that focuses on cytokine receptor antagonists. TTI has a broad network of external R&D collaborations, including several with major pharmaceutical and biotechnology companies.

- 30 -

For further information, please contact:

Niclas Stiernholm, Ph.D.
Chief Executive Officer
Trillium Therapeutics Inc.
96 Skyway Avenue
Toronto, Ontario, M9W 4Y9
Canada

Tel: (416) 595-0627
Fax: (416) 595-5835
niclas@trilliumtherapeutics.com
www.trilliumtherapeutics.com